أرسل هذا في رسالة قصيرة: A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost

 _____     _    _     _  _    _    _    _    _   
|  __ \\  | || | ||  | \| || | || | || | \  / || 
| |  \ || | || | ||  |  ' || | || | || |  \/  || 
| |__/ || | \\_/ ||  | .  || | \\_/ || | .  . || 
|_____//   \____//   |_|\_||  \____//  |_|\/|_|| 
 -----`     `---`    `-` -`    `---`   `-`  `-`